



DUPLICATE

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01620K</b>		APPLICATION NO.: <b>10/654,163</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT: <b>Timothy J. Guzi et al.</b>			
				FILING DATE: <b>09/03/2003</b>		GROUP:	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	DE 102 23 917 A1	12/11/2003	Germany			
	AM	EP 1 199 306 A1	04/24/2002	Europe			
	AN	EP 0 714 898 A1	06/05/1996	Europe			
	AO	WO 02/50079 A1	06/27/2002	WIPO			
	AP	WO 03/091256 A1	11/06/2003	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AQ	Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>J. Natl. Cancer Inst.</i> , 92(5):376-387 (March 1, 2000).					
	AR	Teruki Honma et al., "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design", <i>J. Med. Chem.</i> , 44: 4615-4627 (2001).					
	AS	Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62).					
	AT						
	AU						
	AV						
EXAMINER <i>Don McKey</i>				DATE CONSIDERED <i>6/15/06</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

LAS  
5/3/06